Trial Profile

A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
Indications Mantle-cell lymphoma
Focus Therapeutic Use

Most Recent Events

20 Mar 2024 Planned End Date changed from 30 Apr 2026 to 6 Sep 2024.
13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
02 Nov 2022 Planned primary completion date changed from 19 Oct 2022 to 6 Sep 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com